DR. MULU GELETU
Mulu completed her PhD in human biology at the Department of Internal Medicine Ludwig Maximilians University (LMU), Munich, Germany. Her project focused on the examination of the targets of the fusion protein transcription factor PML-RARα and C/EBPα, which are involved in the pathogenesis of Acute Promyelocytic Leukemia (APL) and Acute Myeloid Leukemia(AML). In 2007 Mulu joined Dr. Leda Raptis's lab as a postdoctoral fellow and was working on the Investigation of the novel pathway of Stat3 activation that is triggered by cadherin engagement.
Since September 2013 has worked as a postdoctoral scientist at the University of Toronto in Dr. Gunning's lab conducting cellular biology. Mulu performs screening of the in-house libraries of STAT’s proteins inhibitors using high-throughput cell basedcytotoxicity assay.
Mulu’s postdoctoral experiences have encompassed studying signal transduction in normal and tumour cells, specifically investigating the role of the STAT3/STAT5 pathways.